Search research articles
Contact Us
Filters
Showing results (51-60 of 55) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 55 results.
Anales Otorrinolaringologicos Ibero-Americanos
|
June 3, 2005
[Malignant external otitis. A pattern to bear always in mind]
F Arias Marzán, L Betancor Martínez, G de Lucas Carmona, et al.
Anales Otorrinolaringologicos Ibero-Americanos
|
August 17, 2006
[Rhabdomyosarcoma of soft palate. A case on purpose]
F Arias Marzán, M De Bonis Redondo, F Redondo Ventura, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response
C Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open
|
April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 55) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 55 results.
Anales Otorrinolaringologicos Ibero-Americanos
|
June 3, 2005
[Malignant external otitis. A pattern to bear always in mind]
F Arias Marzán, L Betancor Martínez, G de Lucas Carmona, et al.
Anales Otorrinolaringologicos Ibero-Americanos
|
August 17, 2006
[Rhabdomyosarcoma of soft palate. A case on purpose]
F Arias Marzán, M De Bonis Redondo, F Redondo Ventura, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response
C Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open
|
April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
Page
of 6